LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

Search

PerkinElmer Inc

Gesloten

SectorGezondheidszorg

0

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Belangrijke statistieken

By Trading Economics

Inkomsten

-8.6M

47M

Verkoop

-21M

699M

K/W

Sectorgemiddelde

46.938

106.172

EPS

1.18

Dividendrendement

0.3

Winstmarge

6.675

Werknemers

11,000

EBITDA

-14M

181M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+20.43% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.30%

2.31%

Volgende Ex Dividend datum

16 jan 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-708M

11B

Vorige openingsprijs

0

Vorige sluitingsprijs

0

Nieuwssentiment

By Acuity

27%

73%

60 / 374 Rangschikking in Healthcare

PerkinElmer Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 nov 2025, 23:36 UTC

Populaire aandelen

Stocks to Watch: Nvidia, Kulicke & Soffa, Regeneron

19 nov 2025, 22:13 UTC

Winsten
Acquisities, Fusies, Overnames

Palo Alto Networks to Buy Chronosphere for $3.35 Billion, Posts Higher 1Q Revenue -- Update

19 nov 2025, 21:55 UTC

Belangrijke Marktbewegers

Amgen Lung Cancer Drug Gets Full Approval From FDA

19 nov 2025, 21:43 UTC

Acquisities, Fusies, Overnames

Palo Alto Networks to Buy Chronosphere for $3.35 Billion

19 nov 2025, 23:55 UTC

Marktinformatie

Gold Rises on Possible Investment Demand -- Market Talk

19 nov 2025, 23:54 UTC

Marktinformatie

BHP Vicuna JV Offers Significant Copper Output, At a Cost -- Market Talk

19 nov 2025, 23:47 UTC

Winsten

Lenovo Group 2Q EPS $2.52 >0992.HK

19 nov 2025, 23:46 UTC

Winsten

Lenovo Group: Delivered Double-Digit Yr-on-Yr Rev Growth Across All Main Business Groups and Sales Geographies >0992.HK

19 nov 2025, 23:45 UTC

Winsten

Lenovo Group 2Q Rev $20.5B >0992.HK

19 nov 2025, 23:42 UTC

Marktinformatie

Nikkei May Rise After Nvidia's Strong Earnings Soothe Investors' Nerves -- Market Talk

19 nov 2025, 23:42 UTC

Marktinformatie

Global Equities Roundup: Market Talk

19 nov 2025, 23:41 UTC

Winsten

Lenovo Group 2Q Adj Net $512.0M Vs. $409.0M >0992.HK

19 nov 2025, 23:41 UTC

Winsten

Lenovo Group 2Q Net $340.0M Vs. Net $359.0M >0992.HK

19 nov 2025, 23:40 UTC

Winsten

Lenovo Group 2Q Rev $20.45B Vs. $17.85B >0992.HK

19 nov 2025, 22:55 UTC

Winsten

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 4th Update

19 nov 2025, 22:41 UTC

Winsten

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 3rd Update

19 nov 2025, 22:30 UTC

Acquisities, Fusies, Overnames

CICC Seeks Trading Halt in Hong Kong, Shanghai Stock Exchange

19 nov 2025, 22:30 UTC

Winsten

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 2nd Update

19 nov 2025, 22:30 UTC

Acquisities, Fusies, Overnames

CICC Plans to Acquire Brokerage Firms via Share-Swap Agreement

19 nov 2025, 22:27 UTC

Acquisities, Fusies, Overnames

China International Capital Plans to Acquire Brokerage Firms Cinda Securities, Dongxing Securities

19 nov 2025, 22:08 UTC

Winsten

ZTO Express (Cayman) 3Q Rev $1.67B >ZTO

19 nov 2025, 22:00 UTC

Winsten

Investors Cheer Blockbuster Nvidia Earnings -- WSJ

19 nov 2025, 21:58 UTC

Winsten
Acquisities, Fusies, Overnames

Palo Alto Networks to Buy Chronosphere for $3.35B, Posts Higher 1Q Rev -- Update

19 nov 2025, 21:52 UTC

Winsten

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- Update

19 nov 2025, 21:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

19 nov 2025, 21:49 UTC

Marktinformatie
Winsten

Nvidia Quiets Investor Fears With Ballooning Demand -- Market Talk

19 nov 2025, 21:38 UTC

Winsten

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- WSJ

19 nov 2025, 21:28 UTC

Acquisities, Fusies, Overnames

Palo Alto Networks to Buy Chronosphere for $3.35B

19 nov 2025, 21:27 UTC

Acquisities, Fusies, Overnames

Exact Sciences Stock Jumps on Reported Deal Interest from Abbott Laboratories -- Barrons.com

19 nov 2025, 21:24 UTC

Winsten
Acquisities, Fusies, Overnames

Palo Alto Networks 1Q Next-Generation Security ARR $5.9 B >PANW

Peer Vergelijking

Prijswijziging

PerkinElmer Inc Prognose

Koersdoel

By TipRanks

20.43% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 111.1 USD  20.43%

Hoogste 125 USD

Laagste 100 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor PerkinElmer Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

8

Buy

3

Hold

0

Sell

Sentiment

By Acuity

60 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat